MedTrace Logo

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

NCT07634640 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-06-09

No results posted yet for this study

Summary

Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Interventions

DRUG

Ferumoxytol infusion

Ferumoxytol infusion followed by cardiac MRI

Sponsors & Collaborators

Principal Investigators

  • Ellen C Keeley, MD, MS · University of Florida

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07634640 on ClinicalTrials.gov